Our History
Quotient’s technology is an extension of the work of one of the great innovators in human-antibody technology, Dr. William Pollack, and has been driven by his son David who Dr. Pollack mentored for over 20 years. Many decades before his work with Quotient, Dr. Pollack led Johnson & Johnson’s research and development function at Ortho. The Ortho family of companies operated one of the largest antibody think tanks and produced antibody-based pharmaceuticals that have saved millions of lives and changed the course of modern medicine.
One of Dr. Pollack’s most prominent innovations, RhoGAM, brought about the virtual elimination of Rh disease. Considered by many to be the most significant product ever made for woman’s health, the product has saved more that 60 million babies from the often-lethal effects of Rh incompatibility. It was approved for sale by the Food & Drug Administration in 1969 under the trade name RhoGAM. Even today, Rh-Immune Globulin is the worldwide standard of care given to millions of women each year.
RhoGAM contains "blocking" antibodies that intercept foreign antigens before these antigens can trigger an immune response in the pregnant woman against her fetus. These blocking antibodies are made from specific donors, similar to Quotient’s current technology platform. Over 250 million doses of RhoGAM have been given safely and it completely blocks the response virtually every time. Dr. Pollack also led the development of Hepatitis B Immune Globulin (HBIG), which confers immediate passive hyper-immunity against Hepatitis B. RhoGAM is on the World Health Organization’s list of Essential Medicines. Dr. Pollack received the Lasker Award in 1980, known as the “American Nobel Prize,” for excellence in biomedical research for his contributions to medicine and health, and recognizing him as “A bold and knowledgeable immunologist with a thorough understanding of the new technology for fractionating serum into its constituents.”
Quotient through years of continued study with Dr. Pollack, patents, proprietary process refinements, development of manufacturing facilities, and testing, is poised to start submissions for advancing the this revolutionary platform of treatment.
One of Dr. Pollack’s most prominent innovations, RhoGAM, brought about the virtual elimination of Rh disease. Considered by many to be the most significant product ever made for woman’s health, the product has saved more that 60 million babies from the often-lethal effects of Rh incompatibility. It was approved for sale by the Food & Drug Administration in 1969 under the trade name RhoGAM. Even today, Rh-Immune Globulin is the worldwide standard of care given to millions of women each year.
RhoGAM contains "blocking" antibodies that intercept foreign antigens before these antigens can trigger an immune response in the pregnant woman against her fetus. These blocking antibodies are made from specific donors, similar to Quotient’s current technology platform. Over 250 million doses of RhoGAM have been given safely and it completely blocks the response virtually every time. Dr. Pollack also led the development of Hepatitis B Immune Globulin (HBIG), which confers immediate passive hyper-immunity against Hepatitis B. RhoGAM is on the World Health Organization’s list of Essential Medicines. Dr. Pollack received the Lasker Award in 1980, known as the “American Nobel Prize,” for excellence in biomedical research for his contributions to medicine and health, and recognizing him as “A bold and knowledgeable immunologist with a thorough understanding of the new technology for fractionating serum into its constituents.”
Quotient through years of continued study with Dr. Pollack, patents, proprietary process refinements, development of manufacturing facilities, and testing, is poised to start submissions for advancing the this revolutionary platform of treatment.
More about Dr. Pollack